Ironwood Pharma

Q2 FY2026 EarningsQ2 FY2026 results showed a significant earnings beat with GAAP EPS of $0.31 vs. $0.32 consensus mean (notably above the $0.28 low), driven by stronger-than-expected LINZESS collaboration profitability. Total revenue of $113.0M was slightly below the $114.7M consensus (-1.47%), but Adjusted EBITDA of $83.0M and the 78% LINZESS commercial margin reflected superior cost efficiency and pricing power. Consequently, management raised FY2026 total revenue guidance to $460M-$485M and Adjusted EBITDA to >$310M, signaling confidence in sustained demand and margin expansion.